https://charts.traderzeitung.de/phases/US00509G2093 string(1439) "{"isin":"US00509G2093","name":"Acumen Pharmaceuticals Inc","stock_id_xnas":19202859,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.59,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":2.6,"close_at":"2026-09-22 15:27:00","complete":true,"perf_pct":0.3861},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.64,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":1.5385},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":2.65,"close_at":"2026-09-23 15:28:00","complete":true,"perf_pct":0.3788},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.3,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-13.2075},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Acumen Pharmaceuticals Aktie News & Nachrichten

[WKN: A3CTP6 | Symbol: ABOS]

Realtimekurs

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Acumen Pharmaceuticals gefunden werden.

Acumen Pharmaceuticals Nachrichtenticker öffnen

MT Newswires 17.06.2026 19:23 Uhr

Acumen Pharmaceuticals übt Option für Alzheimer-Programm unter Verwendung der Technologie von JCR aus

01:22 PM EDT, 06/17/2026 (MT Newswires) -- Acumen Pharmaceuticals (ABOS) hat seine exklusive Option ausgeübt, um im Rahmen einer Zusammenarbeit mit de

MT Newswires 16.06.2026 14:10 Uhr

Acumen Pharmaceuticals benennt 2 Arzneimittelkandidaten zur Behandlung der Alzheimer-Krankheit

08:09 AM EDT, 06/16/2026 (MT Newswires) -- Acumen Pharmaceuticals (ABOS) teilte am Dienstag mit, dass es zwei Entwicklungskandidaten, ACU301 und ACU40